Physician profile
Daniel J Brown
NPI 1417197708
$1,738.49
in general payments reported to CMS, 2019-2025
15 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $255 · 2021: $187 · 2022: $93.73 · 2023: $39.78 · 2024: $35.89 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $997.28 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $313.17 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.74 | 2019-2020 | |
| Philips North America LLC | $60.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.97 | 2019 | |
| Genentech USA, INC. | $42.66 | 2019-2020 | |
| Verona Pharma, INC. | $35.29 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $29.90 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $24.79 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.80 | 2019 | |
| Insmed, INC. | $18.44 | 2019 | |
| Circassia INC. | $18.07 | 2019 | |
| Intuitive Surgical, INC. | $16.99 | 2024 | |
| Optinose US, INC. | $12.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.